Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Tensha Gets Funding To Advance Projects

September 19, 2011 | A version of this story appeared in Volume 89, Issue 38

Tensha Therapeutics, a Cambridge, Mass.-based epigenetics start-up, has gotten $15 million from HealthCare Ventures, a venture capital firm that invests in preclinical and early clinical stage firms. Founded on research out of the Dana-Farber Cancer Institute, Tensha is developing small-molecule bromodomain inhibitors to treat cancer and other diseases. Bromodomains are epigenetic drug targets that play critical roles in regulating the transcription of disease-associated genes. HealthCare Ventures plans to support Tensha’s compound development to the clinical proof-of-concept stage.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.